Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (NASDAQ: PVLA), a clinical-stage biopharmaceutical company specializing in treatments for rare genetic skin diseases, has scheduled its first quarter 2025 financial results and corporate update conference call for May 15, 2025, at 8:30 a.m. ET. The company, which focuses on developing therapies for conditions currently lacking FDA-approved treatments, will provide a webcast with slides accessible through their website's "Events & Presentations" section. Investors can register for dial-in details through a provided link, and a replay will be available approximately 2 hours after the call, remaining archived for 90 days on the company website.
Palvella Therapeutics (PVLA), a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic skin diseases, announced it will ring the Nasdaq opening bell on May 12, 2025. The ceremony, led by CEO Wes Kaupinen along with management team, board members, investors, and advisors, will begin at 9:15 am ET at the Nasdaq MarketSite Tower in New York City.
The event marks Palvella's milestone as a publicly traded, Nasdaq-listed company. The company specializes in developing treatments for serious, rare genetic skin diseases that currently lack FDA-approved therapies. The ceremony will be live-streamed on Nasdaq's X and Facebook pages.
Palvella Therapeutics (NASDAQ: PVLA) has announced groundbreaking research on lymphatic malformations (LMs) with cutaneous involvement in the U.S., to be presented at the Society for Investigative Dermatology Annual Meeting in May 2025.
The medical claims-based analysis, conducted over 7 years using Komodo Health data, reveals an estimated 44,553 high probability LM patients (with ≥2 diagnosis claims) and 48,414 potential LM patients (with ≥1 diagnosis claim), totaling up to 92,967 patients with cutaneous involvement.
The research, led by Dr. Ionela Iacobas from Texas Children's Hospital and David Lapidus from LapidusData, represents the first quantitative analysis of the U.S. LM population using medical claims data. The findings indicate growing demand for multidisciplinary care in complex vascular anomalies treatment.
Palvella Therapeutics (PVLA) has been granted its fifth U.S. patent (No. 12,268,673) for QTORIN™ rapamycin, extending patent protection until 2038. The patent broadens protection for QTORIN™ 3.9% rapamycin anhydrous gel and its clinical applications in treating microcystic lymphatic malformations (LMs).
QTORIN™ rapamycin has received multiple FDA designations including Breakthrough Therapy, Orphan Drug, and Fast Track for treating microcystic LMs. If approved, it could become the first FDA-approved therapy for this rare genetic skin disease and receive seven years of orphan drug market exclusivity in the U.S.
Palvella Therapeutics (PVLA) announced that QTORIN™ rapamycin 3.9% anhydrous gel for treating microcystic lymphatic malformations (LMs) was featured in an oral presentation at the 15th World Congress of Pediatric Dermatology. The presentation highlighted the expansion of the Phase 3 SELVA trial to include children 3-5 years old.
The Phase 2 study showed promising results with 100% of participants showing improvement, including 41.7% 'Very Much Improved' and 58.3% 'Much Improved' according to clinical assessment. The ongoing Phase 3 SELVA trial, targeting 40 subjects across 13 U.S. centers, is expected to deliver top-line results in Q1 2026.
QTORIN™ rapamycin has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations from the FDA, along with a $2.6 million Orphan Products Grant. If approved, it would become the first FDA-approved therapy for microcystic LMs in the U.S.